Name: TB-500 (Thymosin β4 Fragment)
Brand: Research-Grade
Availability: InStock

Question 1

How does TB-500 differ from full-length Thymosin β4?

Accepted Answer

Full-length Thymosin β4 is a 43-amino-acid protein. The TB-500 identified in doping-control research is N-acetylated LKKTETQ — the 17–23 segment of Tβ4 that carries its actin-binding activity. Nearly all published efficacy and safety data, including the human trials, used full-length Tβ4, so results cannot simply be transferred to the fragment.

Question 2

Is TB-500 better combined with BPC-157?

Accepted Answer

No study has tested TB-500 together with BPC-157. The two have different proposed mechanisms in preclinical work — BPC-157 has been linked to VEGFR2 and growth-hormone receptor signaling, Tβ4 to actin-dependent cell migration — but there is no human evidence that combining them adds benefit or is safe.

Question 3

Is there a cancer concern with Thymosin β4?

Accepted Answer

Because Thymosin β4 promotes cell migration and angiogenesis, there is a theoretical concern about effects on existing tumors. Long-term safety data for exogenous Tβ4 or the TB-500 fragment are lacking, so people with a history of cancer should be cautious and discuss any use with their oncologist.

Question 4

Can TB-500 help with cardiac tissue repair?

Accepted Answer

Cardiac repair is one of the most studied applications of full-length Thymosin β4. In mice, Tβ4 activated integrin-linked kinase and Akt, improved early cardiomyocyte survival, and improved cardiac function after coronary artery ligation, and it mobilized adult epicardial progenitor cells that supported new vessel formation. RegeneRx developed Tβ4 for acute myocardial infarction and ran a phase 1 safety study in healthy volunteers. There are no published efficacy results in heart-attack patients, and none at all for the TB-500 fragment.

Question 5

What is the difference between TB-500 and full-length Thymosin Beta-4?

Accepted Answer

The term 'TB-500' is not standardized. Doping-control analysis of a veterinary TB-500 product found N-acetylated LKKTETQ, a 7-residue segment of Thymosin β4, while some suppliers use the name for full-length Tβ4. If you are reading research or buying for laboratory use, check the actual sequence and supporting analysis. The RegeneRx clinical trials used full-length Thymosin β4.

Question 6

How does TB-500 compare to BPC-157 for muscle injuries specifically?

Accepted Answer

There are no head-to-head studies in muscle injury. Thymosin β4 has been studied mainly for cell migration, skin wounds, and cardiac muscle in animals; BPC-157 for tendon, ligament and gastrointestinal healing in rodents. Neither has controlled human trial data for skeletal-muscle injuries.

Question 7

Can TB-500 promote hair regrowth?

Accepted Answer

There is preclinical evidence only. In rats and mice, Thymosin β4 stimulated hair growth, apparently by promoting migration and differentiation of hair follicle stem cells and their progeny. No controlled human trial has tested Tβ4 or the TB-500 fragment for hair loss.

Question 8

What is the specific evidence for TB-500 in cardiac applications?

Accepted Answer

The evidence comes from full-length Thymosin β4. Key preclinical findings: in mice, Tβ4 formed a complex with PINCH and integrin-linked kinase, activated Akt, enhanced early myocyte survival and improved cardiac function after coronary ligation; it was also essential for coronary vessel development and stimulated adult epicardial cells to become vascular progenitors. Clinically, a randomized, placebo-controlled phase 1 study gave intravenous Tβ4 (42–1260 mg, single dose and daily for 14 days) to healthy volunteers and found no dose-limiting toxicity or serious adverse events. A phase 2 trial in heart-attack patients was planned, but no efficacy results in patients have been published.

Question 9

Can TB-500 be used for eye injuries or corneal healing?

Accepted Answer

Corneal repair is one of the most clinically advanced uses of full-length Thymosin β4. RegeneRx's Tβ4 eye drops (RGN-259) were tested in a small randomized, double-masked phase 2 trial in severe dry eye (9 patients), which reported significant improvements in ocular discomfort and corneal staining versus vehicle, and phase 3 trials in dry eye and neurotrophic keratopathy were later started. The synthetic TB-500 fragment has not been tested in the eye, and putting research-grade peptides into the eye carries serious infection risk.

Question 10

How should reconstituted TB-500 be stored, and how long does it remain stable?

Accepted Answer

There are no published stability studies for reconstituted research-grade TB-500, so storage times quoted by vendors are conventions rather than measured data. Peptides are generally kept refrigerated after reconstitution, protected from repeated temperature changes, and discarded if the solution becomes cloudy or discolored.

Origin / Manufacturer	Synthetic
Active Components	TB-500 fragmentBacteriostatic water
Storage	Lyophilized room-temp; reconstituted 2–8°C
Shelf Life	Lyophilized 24+ months
Form Factor	Lyophilized powder (2 mg or 5 mg vial)

TB-500 (Thymosin β4 Fragment)

Specifications

Frequently Asked Questions

Sources & References

Related Peptides

BPC-157

GHK-Cu (Copper Tripeptide-1)